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TheE3ubiquitinligaseCbl-bisanestablishednonredundantnegativeregulatorofT-cellactivation.Cbl-bﬁne-tunestheactivation
threshold of T cells and uncouples T cells from their vital need of a costimulatory signal to mount a productive immune response.
Accordingly, mice deﬁcient in cblb are prone to autoimmunity and reject tumors. The latter has been described to be mediated via
CD8+ T cells, which are hyperactive and more abundant in shrinking tumors of cblb-deﬁcient animals. This might at least also in
part be mediated by resistance of cblb-deﬁcient T cells to negative cues exerted by tumor-associated immuno-suppressive factors,
such as TGF-β and regulatory T cells (Treg). Experiments using cblb-deﬁcient T cells either alone or in combination with vaccines
validate the therapeutic concept of enhancing the eﬃcacy of adoptively transferred lymphocytes to treat malignant tumors. This
paper summarizes the current knowledge about the negative regulatory role of Cbl-b in T-cell activation and its potential thera-
peutic implications for cancer immunotherapy.
1.Introduction
Maintenance of tolerance and induction of T-cell anergy is
criticalforpreventionofautoimmunity.However,inthecase
of malignancies, tumor-induced T-cell anergy and/or toler-
ization induces cancer-associated immune paralysis, which
at least in part contributes to uncontrolled tumor growth
and metastasis. In 2000, two groups independently described
that the E3 ligase Cbl-b functions as a “gate keeper” in peri-
pheralT-celltolerance[1,2].Cbl-bisamemberofthehighly
conserved family of Cbl (casitas b-lineage lymphoma) pro-
teins (Figure 1) and ubiquitinylates substrates by its E3 ligase
activity via its RING domain. The name is derived from the
retroviral oncoprotein v-Cbl, which promotes development
of b-cell lymphoma in mice [3]. Target ubiquitinylation in-
duces either proteasomal or lysosomal degradation regulat-
ing protein turnover or modiﬁes the function of target pro-
teins by altered subcellular localization. Cytoplasmic signal-
ing proteins and nuclear transcription factors tend to be
polyubiquitinated for subsequent proteasomal degradation,
whereas ligand-activated surface receptors, such as receptor
tyrosine kinases, G-protein-coupled receptors, and the T-cell
receptor (TCR) are more often regulated by endocytosis fol-
lowed by lysosomal degradation [4–6]. Substrates can either
be tagged with single (monoubiquitinylation) or multiple
(>4) ubiquitins, the latter leading to polyubiquitinylation.
Thesepolyubiquitinchainsaregenerallylinkedbylysineresi-
dues at position 48 or 63. It is known that polyubiquitintag-
ging of substrates induces their degradation by the 26S pro-
teasome, but polyubiquitin chains might also modify pro-
tein function, for example, by increased cell-surface-recep-
tor turnover or an altered subcellular localization. In con-
trast, monoubiquitinylation has been shown to target cell-
membrane-receptor-associated proteins to the lysosome,
thereby attenuating cell-surface-receptor-mediated signals
by a desensitization process. Thus, monoubiquitinylation
and K63-linked polyubiquitinylation rather regulate protein
traﬃcking and cell-cell interactions, whereas K48-linked2 Clinical and Developmental Immunology
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Figure 1:ThemammalianCblproteinfamily.SchematicrepresentationofthedomainarchitectureofthethreemammalianCblisoforms,c-
Cbl, Cbl-b, and Cbl-c/Cbl-3. The Cbl proteins are highly conserved in the N-terminal region where they comprise a tyrosine-kinase-binding
domain(TKB),whichiscomposedofa4-helixbundle(4H),acalcium-bindingEFdomain,andavariantSH2domainthatislinkedwiththe
RING ﬁnger domain. The COOH-terminal region contains proline-rich stretches, multiple serine and tyrosine phosphorylation sites and
a ubiquitin-associated UBA domain, and a leucine zipper. The Cbl-c isoform lacks the UBA domain and the leucine zipper domain. TKB,
tyrosine-kinase-binding domain; 4H, four-helix bundle; EF, EF hand; SH2, Src-homology domain 2; R, RING “really interesting new gene”
ﬁnger domain; PR, proline rich domain; Y, tyrosine residue; S, serine residue; LZ/UBA, leucine zipper/ubiquitin associated domain.
polyubiquitinylation targets substrates to the proteasome for
degradation [7]. Cbl-b is critically involved in these ubiqui-
tinylation processes, and due to its preferential expression
in immune cells it is centrally involved in the regulation of
immune responses. In more detail, deﬁciency of Cbl-b in T-
cells induces a prominent hyperactive phenotype, resulting
in systemic signs of autoimmunity in animals lacking a func-
tional cblb gene [1, 2]. It is tempting to speculate that inhibi-
tion of its function might also represent a rational approach
to increase T-cell reactivity in the cancer setting. Vice versa,
in the case of an exaggerated immune response, such as seen
in autoimmunity and graft rejections, induction of Cbl-b
mightbeanattractivestrategytolimitT-cellreactivityﬁnally
inducing tolerance.
This review will summarize our current knowledge on
the role of Cbl-b as regulator of T-cell eﬀector function with
a particular focus on its potential therapeutic use as target in
cancer immunotherapy.
2 .Cb l - bisaM e m be ro ft h eCb l
Family of Proteins
Cbl-b is a member of a highly conserved family of Cbl pro-
teins, which in mammals consists of three Cbl genes: Cbl
(also termed c-Cbl, Cbl2,or RNF55), Cbl-b (also termed
RNF56), and Cbl-c/Cbl-3 (also termed Cbl-SL or RNF57)
(Figure 1)[ 8]. Cbl proteins interact with target proteins via
their protein-protein interaction domains, allowing regu-
lation of multiple signaling pathways [9, 10]. The E3 lig-
ase activity of c-Cbl as well as the other Cbl proteins has been
shown to depend on the RING-type zinc ﬁnger domain [11,
12].Datafrominvitroexperimentsusingdeletionmutations
of c-Cbl highlight the critical role of the RING ﬁnger domain
for its E3 ligase activity, as RING ﬁnger domain mutants
could not ubiquitinylate the EGF receptor [13, 14] with the
consequence that ligand-induced c-Cbl-mediated desensi-
tization of EGFR receptor expressing cells to EGF was
disrupted. The RING ﬁnger domain also binds the E2 con-
jugating enzyme and mediates transfer of ubiquitin between
E2 and target substrates [11]. Loss of function mutations in
the E3-ligase domain of cblb in mice phenocopies the cblb-
knockout phenotype [15], again supporting the important
role of the E3 ubiquitin ligase activity for Cbl-b function.
3. Cbl-b as Master Regulator of
T-Cell Effector Functions
Following initial triggering of the antigen receptor, the Src
family kinases Lck and Fyn are recruited and phosphorylate
Zap-70 (zeta-associated protein of 70kDa), which initiates
various downstream signaling pathways [16]. ZAP-70 phos-
phorylates SLP-76 mediating formation of a multisubunit
protein complex including key signaling molecules such as
phosphatidylinositol 3-kinase (PI3K), PLC (phospholipase
C), and Vav1. Activation of these signaling components
results in the activation of PLCy-regulated Ca++ inﬂux, cyto-
skeletal rearrangements via the nucleotide exchange factor
Vav1, Rac,and WASP, and activation of the protein kinase Cθ
(PKCθ)[ 17–19]. The activation step of PKCθ is essential for
an appropriate NFκB stimulation to induce a productive T-
cell immune response in vivo.O fn o t e ,P K C θ also functions
as critical intermediary for inactivation of Cbl-b in response
to costimulation of T-cells through CD28 [20].
Inaphysiologicalcontext,Cbl-bapparentlyactsasaneg-
ative regulator of the T-cell activation process (Figure 2). Ac-
cordingly, cblb-deﬁcient mice are highly susceptible to spon-
taneousandantigen-inducedexperimentalautoimmunedis-
eases [1, 2], despite normal thymic T-cell selection and nor-
mal peripheral T cell numbers. When isolated, cblb-deﬁcient
T cells are hyperproliferative and bypass the requirement
for CD28 costimulation, that is, they proliferate upon sole
stimulationviatheTCRcomparabletoWTTcellsstimulated
with both anti-CD3 and anti-CD28 stimulating antibodies
[1, 2]. Moreover, they produce markedly higher levels ofClinical and Developmental Immunology 3
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Figure 2:Cbl-bfunctionsascentralgatekeeperofT-cellactivation.T-cellstimulationviatheTCRandthesecondcostimulatorysignalleads
to the proximal activation of signaling pathway components. In the absence of costimulation, Cbl-b promotes antigen-speciﬁc T-cell
tolerance. Thus, Cbl-b functions as negative regulator of the activation of T cells that can be, however, bypassed by CD28 stimulation. In
the absence of Cbl-b, T cells are not dependent on a costimulatory signal and proliferative as well as cytokine response upon sole TCR-
activation is comparable to WT T cell stimulated via the TCR and CD28. Note that the signaling cascades and interactions are simpliﬁed and
do not show all molecules involved. For further details please refer to text. Flat-ended lines indicate inhibitory interactions. APC, antigen—
presenting cell; U, Ubiquitin.
proinﬂammatorycytokines,suchasIFN-γ [21].Accordingly,
T-cellanergypromotingconditions,suchasTCRstimulation
in the absence of CD28 costimulation, induce Cbl-b expres-
sion [22].
The TCR induces Ca++ inﬂux and subsequent activation
of the transcription factor NFAT, which leads to activation of
the early growth response genes Egr-2 and Egr-3, which then
increase Cbl-b expression [4, 23]. Cbl-b in turn regulates
recruitment of p85 to CD28 and the TCR zeta chain through
its E3 ubiquitin ligase activity. The observation that PI3K
inhibition reverts enhanced activation of cblb-deﬁcient T-
cells supports the importance of PI3K as Cbl-b target (see
Figure 2)[ 24]. As a consequence of these molecular inter-
actions, induction of anergy is prevented in T cells deﬁcient
in Cbl-b in vitro and in vivo [22]. As an example for the in
vivo relevance of Cbl-b in anergy induction, severe collagen-
induced arthritis can be induced in cblb-deﬁcient mice
even in the absence of the adjuvant, again highlighting the
hyperactive state of the T cell compartment in these animals
[22]. Moreover, in a model of anergy induction in T cells,
which makes use of mice carrying the p14 TCRVa2Vb8.2
transgene recognizing the lymphocytic choriomeningitis
virus (LCMV) p33 peptide presented by MHC class I, the
animalswerechallengedbyrepeatedinjectionsofthecognate
peptide p33. Of note, in this model, cblb-deﬁcient p14 trans-
genic mice challenged with p33 massively activated CD8+ T
cells. This induced signiﬁcant mortality mediated by a severe
cytokine storm [22]. When p14/Rip-gp transgenic mice are
exposed to LCMV, the animals develop diabetes. The rate of
animals developing disease, however, is substantially lower
when p14/Rip-gp transgenic mice are challenged with the
low agonistic peptide LCMV-LF6 (diabetes rate <50%),
whereas injection of cblb- d e ﬁ c i e n ta n i m a l sw i t ht h i sl o w
agonistic peptide induced rapid onset of diabetes paralleled
by an enhanced CTL function [25]. From a mechanistic per-
spective, Cbl-b reduces phosphorylation of PLC-γ1 result-
ing in reduced PLC-γ1 activity in anergic T cells [22]. More-
over, in addition to an intrinsic hyperactive phenotype, cblb4 Clinical and Developmental Immunology
deﬁciency also induces resistance towards negative cues from
the environment, such as soluble TGF-β [26]o re ﬀector im-
munecellsuppressionmediatedbyTreg[27].Thisisalsoref-
lected by decreased generation of inducible Treg in naive
cblb-deﬁcient T cells, as this process is also mediated by
TGF-β [28]. Interestingly, in this particular model the TGF-β
pathway was not shown to be defective, but impaired FoxP3
induction was mediated by increased phosphorylation of
Foxo3a/Foxo1 in cblb-deﬁcient naive CD4+ T cells. In con-
trast, partial TGF-β resistance has been well documented in
CD4+ T cells, which have reduced levels of phosphorylated
SMAD2 upon TGF-β stimulation [26]. Thus, Cbl-b clearly
interacts with the TGF-β signaling pathway, but the exact
molecular background for this observation remains contro-
versial. Nonetheless, resistance of cblb-deﬁcient T cells to
thesenegativeenvironmentalfactorsmightatleastinpartex-
plain their increased antitumor eﬃcacy (see below).
4.Cbl-bas PotentialTarget in
Cancer Immunotherapy
Various reports now linked Cbl-b with anticancer immune
responses. First, Loeser and colleagues demonstrated that
cblb-deﬁcientanimalsarelesssusceptibletotumorformation
in induced as well as spontaneous mouse cancer models rele-
vant for human cancers [29]. Subcutaneous implantation of
TC1 tumor cells as well as induction of spontaneous tumors
by UV irradiation in cblb-deﬁcient animals led to a signiﬁ-
cantly delayed outgrowth of tumors, when compared to WT
animals. Of note, although almost 100% of cblb-deﬁcient
animals had a delayed tumor growth, only a few animals
completely rejected the tumor. It remains to be determined
which variables determine complete rejection versus delayed
tumor growth. However, tumor rejection was paralleled by
an increased inﬁltration of CD3+CD8+ T cells into the
tumor. Depletion experiments corroborated the functional
importance of this particular cell population in tumor rejec-
tion, because CD8-depleted animals showed tumor growth
comparable to WT animals. In addition, increased tumor
inﬁltration of CD8+ T cells also led to markedly increased
amounts of the proinﬂammatory cytokine IFN-γ within the
tumor microenvironment, reﬂecting the boosted immune
response in vivo. Finally this led to an impaired tumor cell
proliferation as quantiﬁed by Ki67 staining and an increased
rate of apoptosis, as determined by caspase-3 detection. The
same group supported this concept by reproducing these
results in mice lacking a functional E3 ligase domain due to a
loss-of-functionmutationwithinthisregionofthecblbgene.
Again, mice that rejected TC1 tumors had increased CD8+
T cells inﬁltrating tumors leading to reduced proliferation
and increased apoptosis [15] .T h e s ed a t ah a v eb e e nf u r t h e r
supported by the observation that cblb-deﬁcient animals also
reject EL4 and EG7 tumor cells [30]a sw e l la ss p o n t a n e o u s
tumors generated by crossing cblb-deﬁcient with ataxia
telangiectasia mutant (ATM) mice, which normally develop
thymic T-cell lymphoma. Interestingly, these authors also
provided genetic evidence that the lack of costimulation is
also of in vivo relevance, as cblb- and CD28-deﬁcient mutant
mice are protected against EL4 cells as well. Thus, these mice
cangenerateaproductiveantitumorimmueresponseevenin
the absence of CD28 [30]. However, when using an adoptive
transfer model, the data are somehow contradictory. First,
Chiang and colleagues described that adoptive transfer of
3×106 polyclonal cblb-deﬁcient CD8+ Tc e ll sa r eh ype racti v e
and reject at least in part EG7 tumors. Moreover, overall sur-
vival in this particular model was signiﬁcantly increased in
animals receiving cblb-deﬁcient versus WT CD8+ T cells. In
contrast, we were not able to detect any protective eﬀect of
5 × 106 polyclonal CD8+ T cells neither in the B16-Ova nor
in the EG7 tumor model. We hypothesized that a second
in vivo activation would be necessary, which allows eﬃcient
activation and selection of tumor model antigen positive T
cells. Thus, we combined the adoptive T-cell transfer with
the application of a dendritic cell (DC) vaccine, which
now induced profound antitumor immune eﬀects in vivo,
which were paralleled by expansion of Ova-speciﬁc CD8+
T cells, higher inﬁltration of CD8+ T cells into the tumor
and higher expression of IFN-γ [21]. This observation is
also supported by data from Yang and colleagues, who
showed that cblb-deﬁcient CD8+ T cells are indeed generally
more eﬃcacious but are nonetheless unable to mediate cur-
ative responses against all tumor types [31]. Using various
tumor models expressing an ovalbumin-tagged version of
HER-2/neu receiving adoptive transfer with WT or cblb-
deﬁcient CD8+ T cells from OT-I T-cell receptor transgenic
donor mice, the authors could demonstrate that at least
some tumors (e.g., NOP18) could not be rejected due to
insuﬃcient inﬁltration of Ova-speciﬁc T cells into the tumor
microenvironment. These data highlight the need of pro-
per migration of tumor-reactive T cells into the tumor mic-
roenvironment to attack cancer cells. If this inﬁltration is
prevented,evenhyperactivecblb- d e ﬁ c i e n tTc e ll sa r en o ta b l e
to kill malignant cells.
5.SummaryandPerspective
Data from knockout animal studies suggest that inactivation
of Cbl-b, which is a nonredundant negative regulator of ef-
fector CD8+ and CD4+ T-cell signaling, represents a rational
approach to improve anticancer T-cell reactivity in vivo.
Proof-of-concept studies using adoptive transfer of isolated
hyperactive T cells from cblb-deﬁcient animals in tumor mo-
dels validate Cbl-b as potential therapeutic target for impro-
vement of antitumor immunotherapy. Future studies will
help to identify strategies allowing in vivo pharmacologi-
cal targeting of Cbl-b activity or genetic modiﬁcation of
Cbl-b expression in adoptively transferred T cells (e.g., by
siRNA).
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